From 64th ASH Annual Meeting & Exposition:
The phase III ALPINE trial demonstrates a progression-free survival advantage for zanubrutinib versus ibrutinib among patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma
Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.
Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.